Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability

2001 ◽  
Vol 100 (6) ◽  
pp. 627-633 ◽  
Author(s):  
Raymond J. PLAYFORD ◽  
Christopher E. MACDONALD ◽  
Denis P. CALNAN ◽  
David N. FLOYD ◽  
Theo PODAS ◽  
...  
Keyword(s):  
Fold Increase ◽  
Preliminary Evidence ◽  
Food Supplement ◽  
Bovine Colostrum ◽  
Gut Permeability ◽  
Health Food ◽  
Drug Induced ◽  
Gastrointestinal Injury ◽  
Prophylactic Measures ◽  
Anti Inflammatory

Non-steroidal anti-inflammatory drugs (NSAIDs) are effective analgesics but cause gastrointestinal injury. Present prophylactic measures are suboptimal and novel therapies are required. Bovine colostrum is a cheap, readily available source of growth factors, which reduces gastrointestinal injury in rats and mice. We therefore examined whether spray-dried, defatted colostrum could reduce the rise in gut permeability (a non-invasive marker of intestinal injury) caused by NSAIDs in volunteers and patients taking NSAIDs for clinical reasons. Healthy male volunteers (n = 7) participated in a randomized crossover trial comparing changes in gut permeability (lactulose/rhamnose ratios) before and after 5 days of 50 mg of indomethacin three times daily (tds) per oral with colostrum (125 ml, tds) or whey protein (control) co-administration. A second study examined the effect of colostral and control solutions (125 ml, tds for 7 days) on gut permeability in patients (n = 15) taking a substantial, regular dose of an NSAID for clinical reasons. For both studies, there was a 2 week washout period between treatment arms. In volunteers, indomethacin caused a 3-fold increase in gut permeability in the control arm (lactulose/rhamnose ratio 0.36±0.07 prior to indomethacin and 1.17±0.25 on day 5, P < 0.01), whereas no significant increase in permeability was seen when colostrum was co-administered. In patients taking long-term NSAID treatment, initial permeability ratios were low (0.13±0.02), despite continuing on the drug, and permeability was not influenced by co-administration of test solutions. These studies provide preliminary evidence that bovine colostrum, which is already currently available as an over-the-counter preparation, may provide a novel approach to the prevention of NSAID-induced gastrointestinal damage in humans.

Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability

2001 ◽  
Vol 100 (6) ◽  
pp. 627 ◽  
Author(s):  
Raymond J. PLAYFORD ◽  
Christopher E. MACDONALD ◽  
Denis P. CALNAN ◽  
David N. FLOYD ◽  
Theo PODAS ◽  
...  
Keyword(s):  
Intestinal Permeability ◽  
Food Supplement ◽  
Bovine Colostrum ◽  
Health Food ◽  
Drug Induced ◽  
Inflammatory Drug ◽  
Anti Inflammatory

scholarly journals Bovine colostrum is a health food supplement which prevents NSAID induced gut damage

Gut ◽  
1999 ◽  
Vol 44 (5) ◽  
pp. 653-658 ◽  
Author(s):  
R J Playford ◽  
D N Floyd ◽  
C E Macdonald ◽  
D P Calnan ◽  
R O Adenekan ◽  
...  
Keyword(s):  
Mouse Model ◽  
Cell Line ◽  
Food Supplement ◽  
Bovine Colostrum ◽  
Intestinal Injury ◽  
Health Food ◽  
Gastrointestinal Injury ◽  
Small Intestinal Injury ◽  
Small Intestinal ◽  
Ht 29

BACKGROUNDNon-steroidal anti-inflammatory drugs (NSAIDs) are effective for arthritis but cause gastrointestinal injury. Bovine colostrum is a rich source of growth factors and is marketed as a health food supplement.AIMSTo examine whether spray dried, defatted colostrum or milk preparations could reduce gastrointestinal injury caused by indomethacin.METHODSEffects of test solutions, administered orally, were examined using an indomethacin restraint rat model of gastric damage and an indomethacin mouse model of small intestinal injury. Effects on migration of the human colonic carcinoma cell line HT-29 and rat small intestinal cell line RIE-1 were assessed using a wounded monolayer assay system (used as an in vitro model of wound repair) and effects on proliferation determined using [3H]thymidine incorporation.RESULTSPretreatment with 0.5 or 1 ml colostral preparation reduced gastric injury by 30% and 60% respectively in rats. A milk preparation was much less efficacious. Recombinant transforming growth factor β added at a dose similar to that found in the colostrum preparation (12.5 ng/rat), reduced injury by about 60%. Addition of colostrum to drinking water (10% vol/vol) prevented villus shortening in the mouse model of small intestinal injury. Addition of milk preparation was ineffective. Colostrum increased proliferation and cell migration of RIE-1 and HT-29 cells. These effects were mainly due to constituents of the colostrum with molecular weights greater than 30 kDa.CONCLUSIONSBovine colostrum could provide a novel, inexpensive approach for the prevention and treatment of the injurious effects of NSAIDs on the gut and may also be of value for the treatment of other ulcerative conditions of the bowel.

Non Steroidal Anti-Inflammatory Drug Induced Damage on Lower Gastro-Intestinal Tract: Is There an Involvement of Microbiota?

2014 ◽  
Vol 9 (3) ◽  
pp. 196-204 ◽  
Author(s):  
Lucia Montenegro ◽  
Giuseppe Losurdo ◽  
Raffaele Licinio ◽  
Maria Zamparella ◽  
Floriana Giorgio ◽  
...  
Keyword(s):  
Intestinal Tract ◽  
Drug Induced ◽  
Inflammatory Drug ◽  
Anti Inflammatory ◽  
Gastro Intestinal Tract

scholarly journals Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy

2021 ◽  
Vol 9 (5) ◽  
pp. e002392
Author(s):  
Lorenzo Iovino ◽  
Laurel A Thur ◽  
Sacha Gnjatic ◽  
Aude Chapuis ◽  
Filippo Milano ◽  
...  
Keyword(s):  
Preliminary Evidence ◽  
Severe Form ◽  
Cell Transplant ◽  
T Cell Therapy ◽  
Cell Therapies ◽  
Novel Drugs ◽  
Prospective Trials ◽  
Systemic Manifestations ◽  
Anti Inflammatory ◽  
Inflammatory Syndrome

COVID-19, the syndrome caused by the infection with SARS-CoV-2 coronavirus, is characterized, in its severe form, by interstitial diffuse pneumonitis and acute respiratory distress syndrome (ARDS). ARDS and systemic manifestations of COVID-19 are mainly due to an exaggerated immune response triggered by the viral infection. Cytokine release syndrome (CRS), an inflammatory syndrome characterized by elevated levels of circulating cytokines, and endothelial dysfunction are systemic manifestations of COVID-19. CRS is also an adverse event of immunotherapy (IMTX), the treatment of diseases using drugs, cells, and antibodies to stimulate or suppress the immune system. Graft-versus-host disease complications after an allogeneic stem cell transplant, toxicity after the infusion of chimeric antigen receptor-T cell therapy and monoclonal antibodies can all lead to CRS. It is hypothesized that anti-inflammatory drugs used for treatment of CRS in IMTX may be useful in reducing the mortality in COVID-19, whereas IMTX itself may help in ameliorating effects of SARS-CoV-2 infection. In this paper, we focused on the potential shared mechanisms and differences between COVID-19 and IMTX-related toxicities. We performed a systematic review of the clinical trials testing anti-inflammatory therapies and of the data published from prospective trials. Preliminary evidence suggests there might be a benefit in targeting the cytokines involved in the pathogenesis of COVID-19, especially by inhibiting the interleukin-6 pathway. Many other approaches based on novel drugs and cell therapies are currently under investigation and may lead to a reduction in hospitalization and mortality due to COVID-19.

scholarly journals In Vivo and In Vitro Toxicodynamic Analyses of New Quinolone-and Nonsteroidal Anti-Inflammatory Drug-Induced Effects on the Central Nervous System

1999 ◽  
Vol 43 (5) ◽  
pp. 1091-1097 ◽  
Author(s):  
Hideki Kita ◽  
Hirotami Matsuo ◽  
Hitomi Takanaga ◽  
Junichi Kawakami ◽  
Koujirou Yamamoto ◽  
...  
Keyword(s):  
Brain Tissue ◽  
Threshold Concentration ◽  
Current Response ◽  
Drug Induced ◽  
Inhibition Ratio ◽  
New Quinolones ◽  
The Central Nervous System ◽  
Anti Inflammatory

ABSTRACT We investigated the correlation between an in vivo isobologram based on the concentrations of new quinolones (NQs) in brain tissue and the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) for the occurrence of convulsions in mice and an in vitro isobologram based on the concentrations of both drugs for changes in the γ-aminobutyric acid (GABA)-induced current response in Xenopus oocytes injected with mRNA from mouse brains in the presence of NQs and/or NSAIDs. After the administration of enoxacin (ENX) in the presence or absence of felbinac (FLB), ketoprofen (KTP), or flurbiprofen (FRP), a synergistic effect was observed in the isobologram based on the threshold concentration in brain tissue between mice with convulsions and those without convulsions. The three NSAIDs did not affect the pharmacokinetic behavior of ENX in the brain. However, the ENX-induced inhibition of the GABA response in the GABAA receptor expressed in Xenopus oocytes was enhanced in the presence of the three NSAIDs. The inhibition ratio profiles of the GABA responses for both drugs were analyzed with a newly developed toxicodynamic model. The inhibitory profiles for ENX in the presence of NSAIDs followed the order KTP (1.2 μM) > FRP (0.3 μM) > FLB (0.2 μM). These were 50- to 280-fold smaller than those observed in the absence of NSAIDs. The inhibition ratio (0.01 to 0.02) of the GABAA receptor in the presence of both drugs was well-fitted to the isobologram based on threshold concentrations of both drugs in brain tissue between mice with convulsions and those without convulsions, despite the presence of NSAIDs. In mice with convulsions, the inhibitory profiles of the threshold concentrations of both drugs in brain tissue of mice with convulsions and those without convulsions can be predicted quantitatively by using in vitro GABA response data and toxicodynamic model.

Sign in / Sign up

Export Citation Format

Share Document